Suppr超能文献

使用固体剂型的品牌药与仿制药之间的差异:体外溶出度测试。

The differences between the branded and generic medicines using solid dosage forms: In-vitro dissolution testing.

作者信息

Al Ameri Mubarak Nasser, Nayuni Nanda, Anil Kumar K G, Perrett David, Tucker Arthur, Johnston Atholl

机构信息

William Harvey Research Institute, Barts and The London, School of Medicine and Dentistry, Queen Mary University of London EC1M 6BQ, UK ; UAE General Hospital, Abu Dhabi, United Arab Emirates.

William Harvey Research Institute, Barts and The London, School of Medicine and Dentistry, Queen Mary University of London EC1M 6BQ, UK.

出版信息

Results Pharma Sci. 2011 Dec 7;2:1-8. doi: 10.1016/j.rinphs.2011.12.001. eCollection 2012.

Abstract

INTRODUCTION

Dissolution is the amount of substance that goes into solution per unit time under standardised conditions of liquid/solid interface, solvent composition and temperature. Dissolution is one of the most important tools to predict the in-vivo bioavailability and in some cases to determine bioequivalence and assure interchangeability.

AIM

To compare the differences in dissolution behaviour of solid dosage forms between innovators (reference products) and their generic counterparts (tested products).

METHODS

Four replicates for each batch of 37 tested medicines was carried out using A PT-DT70 dissolution tester from Pharma Test. A total of 13 branded medicines and 24 generic counterparts were obtained locally and internationally to detect any differences in their dissolution behaviour. They were tested according to the British Pharmacopeia, European Pharmacopeia and the US Pharmacopeia with the rate of dissolution determined by ultra-violet Spectrophotometery.

RESULTS

Most tested medicines complied with the pharmacopoeial specifications and achieved 85% dissolution in 60 min. However, some generic medicines showed significant differences in dissolution rate at 60 and 120 min. Many generic medicines showed a slower dissolution rate than their branded counterparts such as the generic forms of omeprazole 20 mg. Some showed an incomplete dissolution such as the generic form of nifedipine 10 mg. Other generics showed faster dissolution rate than their branded counterpart such as the generic forms of meloxicam 15 mg. Moreover, some generics from different batches of the same manufacturer showed significant differences in their dissolution rate such as the generic forms of meloxicam 7.5 mg. Nevertheless, some generic medicines violated the EMA and the FDA guidelines for industry when they failed to achieve 85% dissolution at 60 min, such as the generic form of diclofenac sodium 50 mg.

CONCLUSION

Most medicines in this study complied with the pharmacopeial limits. However, some generics dissolved differently than their branded counterparts. This can clearly question the interchangeability between the branded and its generic counterpart or even among generics.

摘要

引言

溶出度是指在液体/固体界面、溶剂组成和温度的标准化条件下,单位时间内进入溶液的物质的量。溶出度是预测体内生物利用度的最重要工具之一,在某些情况下可用于确定生物等效性并确保可互换性。

目的

比较创新药(参比制剂)与其仿制药(受试制剂)固体剂型溶出行为的差异。

方法

使用德国 Pharma Test 公司的 A PT-DT70 溶出度测试仪,对 37 种受试药品的每一批次进行 4 次重复测试。从本地和国际上共获取了 13 种品牌药和 24 种仿制药,以检测它们溶出行为的差异。根据英国药典、欧洲药典和美国药典进行测试,溶出速率通过紫外分光光度法测定。

结果

大多数受试药品符合药典规定,在 60 分钟内达到 85%的溶出度。然而,一些仿制药在 60 分钟和 120 分钟时的溶出速率存在显著差异。许多仿制药的溶出速率比其品牌对应产品慢,如 20mg 奥美拉唑的仿制药。一些仿制药表现出不完全溶出,如 10mg 硝苯地平的仿制药。其他仿制药的溶出速率比其品牌对应产品快,如 15mg 美洛昔康的仿制药。此外,同一制造商不同批次的一些仿制药在溶出速率上也存在显著差异,如 7.5mg 美洛昔康的仿制药。然而,一些仿制药在 60 分钟时未达到 85%的溶出度,违反了欧洲药品管理局(EMA)和美国食品药品监督管理局(FDA)的行业指南,如 50mg 双氯芬酸钠的仿制药。

结论

本研究中的大多数药品符合药典规定。然而,一些仿制药的溶出情况与其品牌对应产品不同。这显然对品牌药与其仿制药之间甚至仿制药之间的可互换性提出了质疑。

相似文献

1
The differences between the branded and generic medicines using solid dosage forms: In-vitro dissolution testing.
Results Pharma Sci. 2011 Dec 7;2:1-8. doi: 10.1016/j.rinphs.2011.12.001. eCollection 2012.
6
The Brazilian private pharmaceutical market after the first ten years of the generics law.
J Pharm Policy Pract. 2019 Aug 14;12:18. doi: 10.1186/s40545-019-0179-9. eCollection 2019.
7
Comparison between Branded and Generic Furosemide 40 mg Tablets Using Thermal Gravimetric Analysis and Fourier Transform Infrared Spectroscopy.
J Pharm Bioallied Sci. 2020 Oct-Dec;12(4):489-498. doi: 10.4103/jpbs.JPBS_365_19. Epub 2020 Oct 8.
8
Perceptions of the quality of generic medicines: implications for trust in public services within the local health system in Tumkur, India.
BMJ Glob Health. 2018 Jan 13;2(Suppl 3):e000644. doi: 10.1136/bmjgh-2017-000644. eCollection 2017.
9
Bioequivalence between innovator and generic tacrolimus in liver and kidney transplant recipients: A randomized, crossover clinical trial.
PLoS Med. 2017 Nov 14;14(11):e1002428. doi: 10.1371/journal.pmed.1002428. eCollection 2017 Nov.

引用本文的文献

6
7
Levofloxacin: Insights Into Antibiotic Resistance and Product Quality.
Front Pharmacol. 2019 Aug 14;10:881. doi: 10.3389/fphar.2019.00881. eCollection 2019.
8
Comparison between the dissolution profiles of nine meloxicam tablet brands commercially available in Buenos Aires, Argentina.
Saudi Pharm J. 2018 May;26(4):578-584. doi: 10.1016/j.jsps.2018.01.015. Epub 2018 Feb 9.
9
Quality Attributes and In Vitro Bioequivalence of Different Brands of Amoxicillin Trihydrate Tablets.
Pharmaceutics. 2017 May 20;9(2):18. doi: 10.3390/pharmaceutics9020018.

本文引用的文献

1
Developing the nation's biosimilars program.
N Engl J Med. 2011 Aug 4;365(5):385-8. doi: 10.1056/NEJMp1107285.
2
The pros and cons of generic drugs.
BMJ. 2011 Jul 20;343:d4584. doi: 10.1136/bmj.d4584.
3
A survey to determine the views of renal transplant patients on generic substitution in the UK.
Transpl Int. 2011 Aug;24(8):770-9. doi: 10.1111/j.1432-2277.2011.01268.x. Epub 2011 May 16.
4
Generic and therapeutic substitution: ethics meets health economics.
Int J Clin Pharm. 2011 Jun;33(3):469-70. doi: 10.1007/s11096-011-9500-7. Epub 2011 Mar 24.
5
Generic and therapeutic substitutions: are they always ethical in their own terms?
Pharm World Sci. 2010 Dec;32(6):691-5. doi: 10.1007/s11096-010-9429-2.
6
Comparison of simvastatin tablets from the US and international markets obtained via the Internet.
Ann Pharmacother. 2008 May;42(5):613-20. doi: 10.1345/aph.1K560. Epub 2008 Apr 15.
7
Assessment of the pharmaceutical quality of omeprazole capsule brands marketed in Egypt.
East Mediterr Health J. 2007 Nov-Dec;13(6):1427-37. doi: 10.26719/2007.13.6.1427.
8
The ongoing regulation of generic drugs.
N Engl J Med. 2007 Nov 15;357(20):1993-6. doi: 10.1056/NEJMp078193.
9
A century of dissolution research: from Noyes and Whitney to the biopharmaceutics classification system.
Int J Pharm. 2006 Sep 14;321(1-2):1-11. doi: 10.1016/j.ijpharm.2006.07.011. Epub 2006 Jul 15.
10
Diclofenac sodium multisource prolonged release tablets--a comparative study on the dissolution profiles.
J Pharm Biomed Anal. 2005 Apr 1;37(4):679-85. doi: 10.1016/j.jpba.2004.11.041. Epub 2004 Dec 22.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验